Genetic, epigenetic and expression profiles in alpha-synucleinopathies
Objective: To determine whether each of the alpha-synucleinopathies has distinct methylation and/or expression profiles that distinguishes them from other disorders in this class. Background: The…Modeling Parkinson’s disease pathology by combined injection of fibrilar and monomeric α-synuclein in rat brain
Objective: Development of a fast and progressive Parkinson’s disease (PD) model in rat Background: α-Synuclein is a common link between sporadic and familial PD. Rodent…Antibody binding differences in alpha-synuclein from Parkinson’s disease and multiple system atrophy
Objective: Determine whether alpha-synuclein derived from Parkinson's disease (PD) and multiple system atrophy (MSA) brains has different conformations as defined by biochemical and antibody-based approaches. Background: There…Full sequencing and GWAS markers analysis of SNCA in RBD and progression to synucleinopathies.
Objective: To study the role of SNCA variants in REM sleep Behavior Disorder (RBD) and progression to synucleinopathies. Background: Individuals with properly diagnosed idiopathic RBD…Oligomeric alpha-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson’s disease
Objective: To evaluate alterations in the phosphorylated, oligomeric alpha-synuclein and GBA activity levels in plasma from patients with sporadic Parkinson's disease (sPD), PD patients with…Exploring aging-VMAT2 gene-rotenone interactions in a cell model for Parkinson’s disease
Objective: To develop a Parkinson's disease (PD) model based on aging, vesicular monoamine transporter 2 (VMAT2) gene susceptibility and chronic rotenone exposure in SK-N-SH cell,…The unfolded protein response pathway as a possible therapeutic target for the synucleinopathies
Objective: To investigate whether the pharmacological inhibition of unfolded protein response (UPR) pathway would be beneficial in cellular model of synucleinopathies. Background: It has been…Effect of genetic variation in SNCA and APOE on cerebrospinal fluid protein levels in patients with Parkinson’s disease and controls
Objective: To determine whether genetic variability constitutes a source of heterogeneity in levels of cerebrospinal fluid (CSF) proteins in patients with Parkinson's disease (PD) and…Characteristics of the interaction between different toxic aggregated species of alpha-synuclein and cell membrane
Objective: To determine (1) the interaction rate of each toxic aggregated species of alpha-synuclein (α-Syn) with cell membrane compare to the monomeric form, (2) the…Inhibition of cathepsin D enhances the autophagy lysosome pathway dysfunction and α-synuclein aggregation in experimental parkinsonism
Objective: To explore the mechanism of CTSD inhibition in the dysfunction of autophagy-lysosome pathway and aggregation of α-synuclein in Parkinson's disease. Background: α-synuclein, the main…
- « Previous Page
- 1
- …
- 63
- 64
- 65
- 66
- 67
- …
- 70
- Next Page »